1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Stroke	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	major	_	_	JJ	_	_	_	_	_
5	cause	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	dementia	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	especially	_	_	RB	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	elderly	_	_	JJ	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Specifically	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	one-year	_	_	JJ	_	_	_	_	_
5	post-stroke	_	_	JJ	_	_	_	_	_
6	dementia	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	PSD	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	rates	_	_	NNS	_	_	_	_	_
11	after	_	_	IN	_	_	_	_	_
12	first-ever	_	_	JJ	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	recurrent	_	_	JJ	_	_	_	_	_
15	stroke	_	_	NN	_	_	_	_	_
16	are	_	_	VBP	_	_	_	_	_
17	approximately	_	_	RB	_	_	_	_	_
18	10	_	_	CD	_	_	_	_	_
19	%	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	30	_	_	CD	_	_	_	_	_
22	%	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	respectively	_	_	RB	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Neuropathological	_	_	JJ	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	into	_	_	IN	_	_	_	_	_
4	Alzheimer	_	_	NNP	_	_	_	_	_
5	’s	_	_	POS	_	_	_	_	_
6	disease	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	AD	_	_	NNP	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	have	_	_	VBP	_	_	_	_	_
11	shown	_	_	VBN	_	_	_	_	_
12	that	_	_	IN	_	_	_	_	_
13	AD	_	_	NN	_	_	_	_	_
14	pathology	_	_	NN	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	often	_	_	RB	_	_	_	_	_
17	concomitant	_	_	JJ	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	ischemic	_	_	JJ	_	_	_	_	_
20	lesions	_	_	NNS	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	elderly	_	_	JJ	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	instance	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	evidence	_	_	NN	_	_	_	_	_
5	from	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	Nun	_	_	NNP	_	_	_	_	_
8	Study	_	_	NNP	_	_	_	_	_
9	showed	_	_	VBD	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	lacunes	_	_	NNS	_	_	_	_	_
12	increase	_	_	VBP	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	risk	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	clinical	_	_	JJ	_	_	_	_	_
17	expression	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	cognitive	_	_	JJ	_	_	_	_	_
20	impairment	_	_	NN	_	_	_	_	_
21	more	_	_	JJR	_	_	_	_	_
22	than	_	_	IN	_	_	_	_	_
23	20	_	_	CD	_	_	_	_	_
24	times	_	_	NNS	_	_	_	_	_
25	during	_	_	IN	_	_	_	_	_
26	early	_	_	JJ	_	_	_	_	_
27	Braak	_	_	NNP	_	_	_	_	_
28	stages	_	_	NNS	_	_	_	_	_
29	that	_	_	WDT	_	_	_	_	_
30	were	_	_	VBD	_	_	_	_	_
31	yet	_	_	RB	_	_	_	_	_
32	sufficient	_	_	JJ	_	_	_	_	_
33	to	_	_	TO	_	_	_	_	_
34	produce	_	_	VB	_	_	_	_	_
35	dementia	_	_	NN	_	_	_	_	_
36	symptoms	_	_	NNS	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	follows	_	_	VBZ	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	vascular	_	_	JJ	_	_	_	_	_
5	insults	_	_	NNS	_	_	_	_	_
6	enhance	_	_	VBP	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	clinical	_	_	JJ	_	_	_	_	_
9	expression	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	AD	_	_	NN	_	_	_	_	_
12	pathology	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Vascular	_	_	JJ	_	_	_	_	_
2	dementia	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	more	_	_	RBR	_	_	_	_	_
5	prevalent	_	_	JJ	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	men	_	_	NNS	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	populations	_	_	NNS	_	_	_	_	_
11	affected	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	cerebral	_	_	JJ	_	_	_	_	_
14	small-vessel	_	_	JJ	_	_	_	_	_
15	disease	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	including	_	_	VBG	_	_	_	_	_
18	Asians	_	_	NNPS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	Hispanics	_	_	NNPS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	Africans	_	_	NNPS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	cholinergic	_	_	JJ	_	_	_	_	_
3	system	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	distributed	_	_	VBN	_	_	_	_	_
6	throughout	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	central	_	_	JJ	_	_	_	_	_
9	nervous	_	_	JJ	_	_	_	_	_
10	system	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	playing	_	_	VBG	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	role	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	neurotransmission	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	possibly	_	_	RB	_	_	_	_	_
19	mediating	_	_	VBG	_	_	_	_	_
20	various	_	_	JJ	_	_	_	_	_
21	neuroprotective	_	_	JJ	_	_	_	_	_
22	functions	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	cholinergic	_	_	JJ	_	_	_	_	_
4	neurotransmission	_	_	NN	_	_	_	_	_
5	regulates	_	_	VBZ	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	immune	_	_	JJ	_	_	_	_	_
8	response	_	_	NN	_	_	_	_	_
9	during	_	_	IN	_	_	_	_	_
10	inflammation	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	pathway	_	_	NN	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	involves	_	_	VBZ	_	_	_	_	_
17	nicotinic	_	_	JJ	_	_	_	_	_
18	acetylcholine	_	_	NN	_	_	_	_	_
19	receptors	_	_	NNS	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	nAChRs	_	_	NNS	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	inhibits	_	_	VBZ	_	_	_	_	_
25	peripheral	_	_	JJ	_	_	_	_	_
26	cytokine	_	_	NN	_	_	_	_	_
27	release	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	particular	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	efferent	_	_	JJ	_	_	_	_	_
6	vagus	_	_	JJ	_	_	_	_	_
7	nerve	_	_	NN	_	_	_	_	_
8	may	_	_	MD	_	_	_	_	_
9	release	_	_	VB	_	_	_	_	_
10	acetylcholine	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	Ach	_	_	NN	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	subsequently	_	_	RB	_	_	_	_	_
17	binds	_	_	VBZ	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	macrophage	_	_	NN	_	_	_	_	_
20	receptors	_	_	NNS	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	therefore	_	_	RB	_	_	_	_	_
23	may	_	_	MD	_	_	_	_	_
24	inhibit	_	_	VB	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	release	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	inflammatory	_	_	JJ	_	_	_	_	_
29	factors	_	_	NNS	_	_	_	_	_
30	after	_	_	IN	_	_	_	_	_
31	stroke	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	inflammation	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	excitotoxicity	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	energy	_	_	NN	_	_	_	_	_
9	failure	_	_	NN	_	_	_	_	_
10	following	_	_	VBG	_	_	_	_	_
11	cerebral	_	_	JJ	_	_	_	_	_
12	ischemia	_	_	NN	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	also	_	_	RB	_	_	_	_	_
15	initiate	_	_	VB	_	_	_	_	_
16	intracellular	_	_	JJ	_	_	_	_	_
17	death	_	_	NN	_	_	_	_	_
18	pathways	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	oxidative	_	_	JJ	_	_	_	_	_
21	stress	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	OS	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	structural	_	_	JJ	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	functional	_	_	JJ	_	_	_	_	_
5	changes	_	_	NNS	_	_	_	_	_
6	caused	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	OS	_	_	NNP	_	_	_	_	_
9	led	_	_	VBD	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	cholinergic	_	_	JJ	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	other	_	_	JJ	_	_	_	_	_
14	cellular	_	_	JJ	_	_	_	_	_
15	damage	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Cholinergic	_	_	JJ	_	_	_	_	_
2	deficit	_	_	NN	_	_	_	_	_
3	further	_	_	RBR	_	_	_	_	_
4	caused	_	_	VBD	_	_	_	_	_
5	brain	_	_	NN	_	_	_	_	_
6	atrophy	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	finally	_	_	RB	_	_	_	_	_
9	resulted	_	_	VBD	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	cognitive	_	_	JJ	_	_	_	_	_
12	impairment	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Anticholinergic	_	_	JJ	_	_	_	_	_
2	agents	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	shown	_	_	VBN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	regulate	_	_	VB	_	_	_	_	_
8	OS	_	_	NNP	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	alleviate	_	_	VB	_	_	_	_	_
11	apoptosis	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	key	_	_	JJ	_	_	_	_	_
5	role	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	pathogenesis	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	stroke	_	_	NN	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	dementia	_	_	NN	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	attributed	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	OS	_	_	NNP	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Cholinergic	_	_	JJ	_	_	_	_	_
2	dysfunction	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	related	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	vascular	_	_	JJ	_	_	_	_	_
7	dementia	_	_	NN	_	_	_	_	_
8	.	_	_	.	_	_	_	_	_


1	Specifically	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Ach	_	_	NN	_	_	_	_	_
4	levels	_	_	NNS	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	cerebrospinal	_	_	JJ	_	_	_	_	_
8	fluid	_	_	NN	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	up	_	_	IN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	49	_	_	CD	_	_	_	_	_
13	%	_	_	NN	_	_	_	_	_
14	lower	_	_	JJR	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	patients	_	_	NNS	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	small-vessel	_	_	JJ	_	_	_	_	_
19	vascular	_	_	JJ	_	_	_	_	_
20	dementia	_	_	NN	_	_	_	_	_
21	than	_	_	IN	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	control	_	_	NN	_	_	_	_	_
24	patients	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	suggesting	_	_	VBG	_	_	_	_	_
27	that	_	_	IN	_	_	_	_	_
28	cholinergic	_	_	JJ	_	_	_	_	_
29	agents	_	_	NNS	_	_	_	_	_
30	or	_	_	CC	_	_	_	_	_
31	cholinesterase	_	_	NN	_	_	_	_	_
32	inhibitors	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	both	_	_	DT	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	which	_	_	WDT	_	_	_	_	_
37	increase	_	_	VBP	_	_	_	_	_
38	the	_	_	DT	_	_	_	_	_
39	Ach	_	_	NN	_	_	_	_	_
40	level	_	_	NN	_	_	_	_	_
41	,	_	_	,	_	_	_	_	_
42	could	_	_	MD	_	_	_	_	_
43	be	_	_	VB	_	_	_	_	_
44	used	_	_	VBN	_	_	_	_	_
45	to	_	_	TO	_	_	_	_	_
46	treat	_	_	VB	_	_	_	_	_
47	such	_	_	JJ	_	_	_	_	_
48	patients	_	_	NNS	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	One	_	_	CD	_	_	_	_	_
2	pilot	_	_	NN	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	acetylcholinesterase	_	_	NN	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	AChE	_	_	NN	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	inhibitor	_	_	NN	_	_	_	_	_
11	promoted	_	_	VBN	_	_	_	_	_
12	functional	_	_	JJ	_	_	_	_	_
13	recovery	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	elderly	_	_	JJ	_	_	_	_	_
16	patients	_	_	NNS	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	cognitive	_	_	JJ	_	_	_	_	_
19	impairment	_	_	NN	_	_	_	_	_
20	who	_	_	WP	_	_	_	_	_
21	had	_	_	VBD	_	_	_	_	_
22	suffered	_	_	VBN	_	_	_	_	_
23	stroke	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_
25	In	_	_	IN	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	rat	_	_	NN	_	_	_	_	_
28	model	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	chronic	_	_	JJ	_	_	_	_	_
31	ischemic	_	_	JJ	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	AChE	_	_	NN	_	_	_	_	_
34	activity	_	_	NN	_	_	_	_	_
35	was	_	_	VBD	_	_	_	_	_
36	slightly	_	_	RB	_	_	_	_	_
37	decreased	_	_	VBN	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	frontal	_	_	JJ	_	_	_	_	_
41	cortex	_	_	NN	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	but	_	_	CC	_	_	_	_	_
44	muscarinic	_	_	JJ	_	_	_	_	_
45	acetylcholine	_	_	NN	_	_	_	_	_
46	receptor	_	_	NN	_	_	_	_	_
47	M1	_	_	NN	_	_	_	_	_
48	was	_	_	VBD	_	_	_	_	_
49	gradually	_	_	RB	_	_	_	_	_
50	depleted	_	_	VBN	_	_	_	_	_
51	in	_	_	IN	_	_	_	_	_
52	cerebral	_	_	JJ	_	_	_	_	_
53	cortex	_	_	NN	_	_	_	_	_
54	,	_	_	,	_	_	_	_	_
55	striatum	_	_	NN	_	_	_	_	_
56	and	_	_	CC	_	_	_	_	_
57	hippocampus	_	_	NN	_	_	_	_	_
58	that	_	_	WDT	_	_	_	_	_
59	are	_	_	VBP	_	_	_	_	_
60	involved	_	_	VBN	_	_	_	_	_
61	in	_	_	IN	_	_	_	_	_
62	cognitive	_	_	JJ	_	_	_	_	_
63	function	_	_	NN	_	_	_	_	_
64	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	stroke	_	_	NN	_	_	_	_	_
6	patients	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	reduced	_	_	VBN	_	_	_	_	_
9	AChE	_	_	NN	_	_	_	_	_
10	activity	_	_	NN	_	_	_	_	_
11	was	_	_	VBD	_	_	_	_	_
12	correlated	_	_	VBN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	lower	_	_	JJR	_	_	_	_	_
15	survival	_	_	NN	_	_	_	_	_
16	rate	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Taken	_	_	VBN	_	_	_	_	_
2	together	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	these	_	_	DT	_	_	_	_	_
5	results	_	_	NNS	_	_	_	_	_
6	suggest	_	_	VBP	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	AChE	_	_	NN	_	_	_	_	_
9	dysfunction	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	result	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	stroke	_	_	NN	_	_	_	_	_
15	rather	_	_	RB	_	_	_	_	_
16	than	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	cause	_	_	NN	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	further	_	_	JJR	_	_	_	_	_
21	neurodegeneration	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	AChE	_	_	NN	_	_	_	_	_
4	inhibitors	_	_	NNS	_	_	_	_	_
5	exert	_	_	VBP	_	_	_	_	_
6	no	_	_	DT	_	_	_	_	_
7	effect	_	_	NN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	stroke	_	_	NN	_	_	_	_	_
10	risk	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	dementia	_	_	NN	_	_	_	_	_
13	patients	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	observations	_	_	NNS	_	_	_	_	_
3	suggest	_	_	VBP	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	Ach	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	AChE	_	_	NNP	_	_	_	_	_
8	function	_	_	NN	_	_	_	_	_
9	may	_	_	MD	_	_	_	_	_
10	predict	_	_	VB	_	_	_	_	_
11	post-stroke	_	_	JJ	_	_	_	_	_
12	neuronal	_	_	JJ	_	_	_	_	_
13	damage	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	date	_	_	VB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	only	_	_	RB	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	few	_	_	JJ	_	_	_	_	_
7	blood	_	_	NN	_	_	_	_	_
8	biomarkers	_	_	NNS	_	_	_	_	_
9	for	_	_	IN	_	_	_	_	_
10	predicting	_	_	VBG	_	_	_	_	_
11	PSD	_	_	NN	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	been	_	_	VBN	_	_	_	_	_
14	examined	_	_	VBN	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	e.	_	_	FW	_	_	_	_	_
17	g.	_	_	FW	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	D-amino	_	_	NN	_	_	_	_	_
20	acid	_	_	NN	_	_	_	_	_
21	oxidase	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	β-secretase	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	inflammation	_	_	NN	_	_	_	_	_
27	markers	_	_	NNS	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	few	_	_	JJ	_	_	_	_	_
32	studies	_	_	NNS	_	_	_	_	_
33	have	_	_	VBP	_	_	_	_	_
34	focused	_	_	VBN	_	_	_	_	_
35	on	_	_	IN	_	_	_	_	_
36	changes	_	_	NNS	_	_	_	_	_
37	in	_	_	IN	_	_	_	_	_
38	blood	_	_	NN	_	_	_	_	_
39	cholinesterase	_	_	NN	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	ChE	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	levels	_	_	NNS	_	_	_	_	_
44	and	_	_	CC	_	_	_	_	_
45	activity	_	_	NN	_	_	_	_	_
46	in	_	_	IN	_	_	_	_	_
47	patients	_	_	NNS	_	_	_	_	_
48	with	_	_	IN	_	_	_	_	_
49	PSD	_	_	NN	_	_	_	_	_
50	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	plasma	_	_	NN	_	_	_	_	_
3	Ach	_	_	NNP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	metabolized	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	AChE	_	_	NNP	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	butylcholinesterase	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	BChE	_	_	NNP	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	present	_	_	JJ	_	_	_	_	_
16	study	_	_	NN	_	_	_	_	_
17	examined	_	_	VBN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	functional	_	_	JJ	_	_	_	_	_
20	activities	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	these	_	_	DT	_	_	_	_	_
23	two	_	_	CD	_	_	_	_	_
24	enzymes	_	_	NNS	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	population	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	patients	_	_	NNS	_	_	_	_	_
30	with	_	_	IN	_	_	_	_	_
31	chronic	_	_	JJ	_	_	_	_	_
32	ischemic	_	_	JJ	_	_	_	_	_
33	stroke	_	_	NN	_	_	_	_	_
34	(	_	_	-LRB-	_	_	_	_	_
35	IS	_	_	NNS	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_

